Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Guardant Health's interest expense for the
three
months ended in Mar. 2022 was $ -0.6 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2022 was $-2.6 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Guardant Health's Operating Income for the
three
months ended in Mar. 2022 was $ -123.3 Mil. Guardant Health's Interest Expense for the
three
months ended in Mar. 2022 was $ -0.6 Mil.
Guardant Health did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Guardant Health Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (NAS:GH) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Guardant Health's Interest Expense for the
three
months ended in Mar. 2022 was $-0.6 Mil. Its
Operating Income
for the
three
months ended in Mar. 2022 was $-123.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2022 was $1,360.8 Mil.
Guardant Health's Interest Coverage for the quarter that ended in Mar. 2022 is calculated as
| Guardant Health did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Guardant Health Business Description
Traded in Other Exchanges
Address
505 Penobscot Drive, Redwood City, CA, USA, 94063
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
Executives
| Talasaz Amirali |
director, officer: Chairman, President and COO |
18 ISABELLA AVENUE ATHERTON CA 94027 |
| Kaul Samir |
director |
C/O KHOSLA VENTURES 3000 SAND HILL ROAD, BLDG. 3, SUITE 170 MENLO PARK CA 94025 |
| Meresman Stanley J |
director |
2071 HUNTINGTON LANE LOS ALTOS CA 94024 |
| Svf Bluebird (cayman) Ltd |
10 percent owner |
C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
| Svf Enterprise (cayman) Ltd |
10 percent owner |
C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
| Sb Investment Advisers (uk) Ltd |
10 percent owner |
69 GROSVENOR STREET LONDON X0 W1K 3JP |
| Softbank Vision Fund (aiv M1) L.p. |
10 percent owner |
251 LITTLE FALLS DRIVE WILMINGTON DE 19808 |
| Svf Endurance (cayman) Ltd |
10 percent owner |
C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
| Clark Ian T |
director |
SOLAZYME, INC. 225 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080 |
| Eltoukhy Helmy |
director, officer: Chief Executive Officer |
2 BARRY LANE ATHERTON CA 94027 |
| Bertocci Derek A |
officer: Chief Financial Officer |
3070 ORCHARD DRIVE SAN JOSE CA 95134 |
| Saia John G. |
officer: See Remarks |
C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063 |
| Gadde Vijaya |
director |
C/O TWITTER INC 1355 MARKET STREET SUITE 900 SAN FRANCISCO CA 94103 |
| Jallal Bahija |
director |
120 MONUMENT CIRCLE INDIANAPOLIS IN 46204 |
| Nishar Dipchand |
director |
C/O LINKEDIN CORPORATION 2029 STIERLIN COURT MOUNTAIN VIEW CA 94043 |
Guardant Health Headlines
By Seekingalpha 2022-01-24
By Seekingalpha 2022-02-24
By Seekingalpha 2021-11-04
By tipranks.com 2022-03-10
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
2.82(6.06%) Volume: 393,329 12:06PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:GH has been successfully added to your 
